Search Results
Viewing: 7921-7930 of 11692 | All
News
New Study Identifies the Medical and Financial Impact of Drug-related Poisonings Treated in U.S. Emergency Departments
Over the past decade, drug-related poisonings have been on the rise in the United States. In fact, in many states drug-related poisoning deaths have now surpassed motor vehicle crash fatalities to become the leading cause of injury death.
Article
Baby Carriers
An average of one child aged 5 years and younger is treated in U.S. hospital emergency departments every two hours for a carrier-related injury.
Blog
Furniture Tip-Overs: Tips to Keep Your Kids Safe
In 2019, 11,521 children visited the emergency department for injuries from furniture or TV tip-overs. That’s one child every 46 minutes. When children climb on desks, cabinets, or bookshelves, the furniture can tip over and hurt them.
Blog
Choosing a Stroller: Best Tips to Keep Your Child Safe
Parents with young children have so many decisions to make and so many pieces of “equipment” to get. One of the bigger decisions is choosing a stroller that fits both your baby and your family’s lifestyle. There are many different options out there and it can get overwhelming.
What's Your Passion?
Explore career opportunities for making an impact that truly matters.
Article
Research Staff Careers
The research we do here at Nationwide Children's impacts how we care for patients from Ohio and from around the world.
Article
Research Faculty Careers
The Abigail Wexner Research Institute (AWRI) at Nationwide Children’s is ranked among the top 10 freestanding children’s hospitals based on NIH funding. On a continuing trajectory of rapid growth, AWRI is looking for new faculty to drive the next generation of discovery at Nationwide Children's.
News
FDA Approves First Gene Therapy Treatment for Duchenne Muscular Dystrophy Developed at the Abigail Wexner Research Institute at Nationwide Children’s Hospital
Today, the Abigail Wexner Research Institute at Nationwide Children’s Hospital praised the Food and Drug Administration (FDA) for its accelerated approval of SRP-9001/ELEVIDYS for Duchenne muscular dystrophy (DMD) following decades of research in its Center for Gene Therapy to help patients with neuromuscular diseases.
Article
Flanigan Lab
Under the direction of Kevin Flanigan, MD, the Flanigan Lab focuses on the genetic and molecular characterization of inherited neuromuscular diseases, and toward the development of therapies directed toward these diseases.